

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H77BEBB0F8F7EN.html>

Date: August 2022

Pages: 116

Price: US\$ 3,500.00 (Single User License)

ID: H77BEBB0F8F7EN

Abstracts

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis.

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed and Preclinical stages are 1, 1, 4, 1 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Melanoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma),

Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Colorectal Cancer, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Mycosis Fungoides, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Anal Cancer, Anaplastic Astrocytoma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Bone Disorders, Cervical Cancer, CNS Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Drug Addiction, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Muscle Invasive Bladder Cancer (MIBC), Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Parkinson's Disease, Penile Cancer, Peripheral T-Cell Lymphomas (PTCL), Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Unspecified B-Cell Lymphomas, Ureter Cancer, Urethral Cancer and Vulvar Cancer.

The latest report Histone Deacetylase 3 - Drugs In Development, 2022, outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies

Involved in Therapeutics Development

4D Pharma Plc

BioMarin Pharmaceutical Inc

Curis Inc

GNT Biotech and Medicals Corp

Kdac Therapeutics Inc

Medivir AB

Merck & Co Inc

Oceanyx Pharmaceuticals Inc

OnKure Inc

Shenzhen Chipscreen Biosciences Co Ltd

Shuttle Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles

entinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

fimepinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

GNTbm-04 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GNTbm-38 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KDAC-0001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

largazole - Drug Profile

Product Description

Mechanism Of Action

History of Events

MRx-0029 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MRX-1299 - Drug Profile

Product Description

Mechanism Of Action

History of Events

OKI-179 - Drug Profile

Product Description

Mechanism Of Action

History of Events

OKI-422 - Drug Profile

Product Description

Mechanism Of Action

History of Events

remetinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

RG-2833 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit HDAC1, HDAC2 and HDAC3 for Burkitt Lymphoma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

SP-1161 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SP-1303 - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

History of Events

tucidinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

vorinostat - Drug Profile

Product Description

Mechanism Of Action

History of Events

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Discontinued Products

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product

Development Milestones

Featured News & Press Releases

Jun 02, 2022: OnKure Therapeutics announces first patient dosed in the phase 1b/2 Nautilus trial of OKI-179 in combination with binimetinib in patients with advanced NRAS-mutated melanoma

Apr 08, 2022: OnKure Therapeutics announces promising preclinical data on OKI-179 in RAS-mutated tumor models presented in a late-breaking session at AACR

Mar 08, 2022: OnKure Therapeutics to present late-breaking preclinical data on OKI-179 at the AACR Annual Meeting 2022

Feb 22, 2022: 4D pharma announces FDA clearance of IND application for Live Biotherapeutic MRx0029 for the treatment of Parkinson's disease

Dec 14, 2021: OnKure Therapeutics announces positive topline first-in-human phase 1 results for OKI-179

Dec 01, 2021: Licensing partner of Shenzhen Chipscreen Biosciences - HUYABIO International, receives regulatory approval for Chidamide monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

Nov 30, 2021: HUYABIO International receives regulatory approval for Hiyasta monotherapy of peripheral t-cell lymphoma In Japan

Nov 25, 2021: Approval for additional indication of Hiyasta tablets for relapsed or refractory PTCL treatment in Japan

Nov 18, 2021: Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published

Oct 19, 2021: HUYABIO International launches Hiyasta as monotherapy for adult T-cell leukemia/lymphoma in Japan

Oct 07, 2021: Kyowa Kirin announces discontinuation for developing KHK237 (Entinostat)

Sep 21, 2021: HUYABIO announces first patient treated in a pivotal study of HBI-8000 combined with Opdivo (nivolumab) in patients with advanced melanoma

Aug 16, 2021: University of North Carolina Lineberger Comprehensive Cancer Center: Experimental drug that boosts immunotherapy shows promise in bladder cancer study

Aug 16, 2021: Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement

Aug 16, 2021: Inhibitor drug entinostat 'Primes' the body to better respond to anti-cancer treatment with immunotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 4D Pharma Plc, 2022
Pipeline by BioMarin Pharmaceutical Inc, 2022
Pipeline by Curis Inc, 2022
Pipeline by GNT Biotech and Medicals Corp, 2022
Pipeline by Kdac Therapeutics Inc, 2022
Pipeline by Medivir AB, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Oceanyx Pharmaceuticals Inc, 2022
Pipeline by OnKure Inc, 2022
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Pipeline by Shuttle Pharmaceuticals Inc, 2022
Pipeline by Syndax Pharmaceuticals Inc, 2022
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H77BEBB0F8F7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H77BEBB0F8F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970